Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Roche test showed Tecentriq helped vs bladder cancer

Roche Holding’s Tecentriq drug combined with platinum-based chemotherapy reduced the risk of the disease worsening or death in patients with advanced bladder cancer.

Read More »

Pfizer’s Rivipansel Fails to Meet Primary and Secondary Efficacy Endpoints in Sickle Cell Trial

Pfizer announced that the company’s Phase III RESET clinical trial evaluating rivipansel in sickle cell disease (SCD) failed to meet the study’s primary and key secondary efficacy endpoints.

Read More »

Amicus Therapeutics’ Gene Therapy for Rare, Fatal Childhood Disease Shows Promise in Study

Amicus Therapeutics announced positive interim results from the company’s CLN6 Batten disease gene therapy program.

Read More »

Novartis’ Kisqali Effective in Postmenopausal Women with Breast Cancer

Novartis’ Phase III MONALEESA-3 clinical trial of Kisqali (ribociclib) hit the key secondary endpoint, overall survival.

Read More »

Zogenix Prepares for Second Shot at Seizure Drug Submission

Zogenix plans to resubmit a New Drug Application for Fintepla (fenfluramine) to treat seizures associated with Dravet syndrome.

Read More »

Myovant to Seek FDA Approval for Uterine Fibroid Treatment Following Successful Trial

Myovant is preparing to seek regulatory approval for the company’s once-daily relugolix combination therapy for the treatment of uterine fibroids following positive Phase III results that showed a 71.2 percent response rate in patients.

Read More »

ViiV’s Investigational HIV Drug Finds Success in Hard-to-Treat Patient Population

GlaxoSmithKline, Pfizer and Shinogi’s joint venture ViiV Healthcare said the Phase III BRIGHTE study hit 96-week endpoints in heavily treatment-experienced adults with HIV-1 infection.

Read More »

Acadia’s schizophrenia treatment misses late-stage main goal; shares fall 16%

Acadia Pharmaceuticals Inc.’s add-on treatment pimavanserin for schizophrenia failed to meet the main goal in a late-stage study.

Read More »

Intec Pharma Crashes as Phase III Parkinson’s Treatment Fails in Comparison Trial

Shares of Israel-based Intec Pharma Ltd. were down nearly 82 percent after the company announced that the Phase III Parkinson’s disease therapy Accordion Pill failed to demonstrate statistical superiority to treatment with Sinemet, a combination of carbidopa and levodopa.

Read More »

GSK drug helps ovarian cancer patients live longer

GlaxoSmithKline Plc’s cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom